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Local control rates for Giant Cell Tumor of Bone (GCT) have been reported in a large number of retrospective series. However,
there remains a lack of consensus with respect to the need for a surgical adjuvant when intralesional curettage is performed. We
havesystematicallyreviewedtheliteratureandidentiﬁedsixstudiesinwhichtwogroupsfromthesamepatientcohortweretreated
with intralesional curettage and high-speed burring with or without a chemical or thermal adjuvant. Studies were evaluated for
quality and pooled data was analyzed using the ﬁxed eﬀects model. Data from 387 patients did not indicate improved local control
with the use of surgical adjuvants. Given the available data, we conclude that surgical adjuvants are not required when meticulous
tumor removal is performed.
1.Introduction
Giant Cell Tumor of Bone (GCT) is a primary bone tumor
of mesenchymal origin presenting as a localized osteolytic
lesion. GCT typically aﬀects the meta-epiphyseal region of
long bones, mainly the distal femur and the proximal tibia
with a peak incidence in the 3rd and 4th decades of life
[1, 2]. Despite the fact that it is classiﬁed as a benign
bone tumor, GCT exhibits locally aggressive features with an
unpredictable course of progression [1, 3, 4].
Although close to 100% local control is achieved with
en bloc resection [5], this type of procedure is commonly
associated with functional disabilities due to the peri-
articular location of many of GCTs [6]. Hence, intralesional
curettage has been widely accepted as the standard of care
for GCT of bone. This method of treatment carries a
signiﬁcantly higher recurrence rate with various recurrence
rates ranging from approximately 13% to 49% [2, 5, 7–9]. In
anattempttoreducethesehighlocalrecurrencerates,several
toxic or thermal adjuvants have been advocated to provide
local control. These include phenol, polymethylmethacrylate
(PMMA), argon beam coagulation, anhydrous alcohol, and
liquid nitrogen [10–15]. Although PMMA can be used as
structural ﬁller, it is believed to cause thermal injury to local
cells and therefore acts as a surgical adjuvant [16].
There are, however, drawbacks to the use of toxic or
thermal adjuvants. Phenol is considered cytotoxic with
reported cases of hepatotoxicity and pulmonary edema and
ﬁbrosis. It is readily absorbable through the skin, mucosa,
and open wounds. The acutelethal dose has been noted to be
1-2gparenterallyand10gdermally[17,18].LiquidNitrogen
has been associated with local tissue damage and risk
of infection through particulate transfer [19]. Inhalational
accidents have been reported with resultant acute serious
upper airway injuries [20]. These growing concerns, as well
as the ﬁnancial burden of such practice, led to questioning
the eﬃcacy of these chemicals in reducing recurrence rates of
GCT when used as local adjuvants.
In a multicenter retrospective Scandinavian sarcoma
study, 294 patients with GCT were followed for an average
of 5 years [14]. The authors found cementation to be an
eﬀective method for reducing the recurrence rates after2 Sarcoma
intralesional surgery. Similar results were reported by Becker
et al. in their multicenter retrospective study of 298 patients
treated between 1945 and 1998 [11]. Both studies showed a
statistically signiﬁcant diﬀerence favoring the use of PMMA
as a local adjuvant. A recent study by Errani et al. found
that “aggressive curettage” using a combination of phenol,
alcohol and cement following intralesional surgery was
associated with the lowest recurrence rate of the series of
12.5% [21].
In contrast, Blackley et al. reported on the recurrence
rates of GCT in 59 patients between 1986 and 1996 treated
with intralesional procedures using high-speed burr alone
[7]. Mean follow up was 80 months and reported recurrence
rate was 12%. They concluded that the adequacy of the
removal of the tumor rather than the use of adjuvant modal-
ities is what determines the risk of recurrence. In another
multicenter study that included 186 patients, Turcotte et al.
found no diﬀerence in the recurrence rates when comparing
highspeed burraloneto otherlocaladjuvants[2].Trieb etal.
also found no signiﬁcant diﬀerence in local recurrence rates
with and without phenol as an adjuvant and emphasized the
importance of adequate tumor removal [22].
Given the discrepant conclusions of the various studies
on the surgical management of GCT with respect to the
necessity of a chemical or thermal adjuvant to reduce local
recurrence rates, the purpose of this study was to perform a
systematic review of the literature and meta-analysis of the
available data to compare the eﬃcacy of toxic adjuvants and
high-speedburringcomparedtohigh-speedburringalonein
the surgical management of GCT.
2.MaterialsandMethods
2.1. Literature Search. A literature review was performed on
all studies that assessed the eﬀectof local adjuvant modalities
on the recurrence rates of giant cell tumors. Searches
through the Medline and EMBASE electronic databases
were conducted through September 2009. The search was
performed by two independent assessors and the results were
compared. Keywords used in the search process included:
giant cell tumor, bone, surgery, adjuvant, and recurrence.
These were arranged using varying combinations of “AND,”
“NOT,” and “OR,” and the results were limited to studies
published or translated into the English language. Additional
searches were performed manually through reference lists
of review articles and relevant studies. Authors of potential
eligible studies were also contacted to obtain unpublished
data.
3. Inclusion and Exclusion Criteria
Studies were included if they reported on patients from the
same cohort who were surgically treated for giant cell tumor
of bone within two distinct comparison groups: one group
treated with curettage and high speed burr followed by a
local adjuvant, and the other group treated with curettage
and high speed burr alone. Other inclusion criteria were
studies that reported local recurrence as a primary outcome
and those with at least 2 years of follow-up. Axial and
appendicular tumor locations were included.
3.1. Quality Assessment. Eligible studies were evaluated
by two independent reviewers for their quality using
the Methodological Index for Nonrandomized Studies
(MINORs) [23] scale and the Newcastle Ottawa Quality
assessment scale (NOS) (http://www.ohri.ca/programs/clin-
ical epidemiology/oxford.htm). The scales allocate a maxi-
mum of nine points for quality of selection, comparability,
exposure, and outcome of study participants.
3.2. Outcome Measures. The primary outcome targeted for
analysis was the local recurrence rate, deﬁned as radiological
and pathological evidence of local disease recurrence neces-
sitating further surgical intervention.
3.3. Statistical Analysis. The Comprehensive Meta-analysis
version 1 software (Biostat Inc, NJ) was used for data
analysis.Oddsratios(OR)and95%conﬁdenceintervals(CI)
are reported. Heterogeneity among studies was tested using
the Cochrane Q test with a P-value set at a.1 for signiﬁcance.
The I-squared statistic is the percentage of total variation
across studies due to heterogeneity. We had planned to use
random eﬀect model in the presence of heterogeneity and
ﬁxed eﬀect model otherwise. A meta-analysis of pooled odds
ratios was performed and an alpha of 0.05 was considered a
criterion for statistical signiﬁcance.
4. Results
4.1. Literature Search. Our initial search through the elec-
tronic databases yielded 2557 titles. After manual review
of titles and abstracts, 2544 articles were excluded and
13 articles were determined relevant. Full text review was
performed and ﬁve studies were excluded as they did not
meet the inclusion criteria (appropriate comparison groups
not present within the patient cohort). Two further studies
were excluded following corresponding author contact due
to unavailable original patient data regarding the use of a
high-speed burr [11, 14]. Therefore, six studies were found
to meet the criteria and were included in this meta-analysis
(Figure 1)[ 2, 3, 9, 12, 22, 24].
4.2. Study Characteristics and Methodological Assessment. All
six studies evaluated adult patients diagnosed with primary
or recurrent giant cell tumor of bone treated with curettage
and high speed burr with or without a local adjuvant.
Adjuvant modalities used varied between phenol, PMMA,
and liquid nitrogen (Table 1). Ninety-six percent of the
patients included in the papers were treated for lesions of the
appendicular skeleton. The level of agreement was very high
between the two reviewers with median score of 7 for both
reviewersusingNewcastle-Ottawaquestionnaireandmedian
score of 7.5 for both reviewers using the MONIRs tool.
4.3.LocalRecurrence. Atotalof387patientswereincludedin
the analysis, 323 treated with high speed burring and a localSarcoma 3
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Figure 1: Literature search ﬂow diagram.
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Figure 2: Forest plot for odds ratios of overall recurrence by type of intervention (95% CI, 0.67–3.35, P = .32).
adjuvant and 64 patients treated with curettage and high
speed burring alone. Sixty-six patients (20%) in the adjuvant
group suﬀered a local recurrence while 15 patients (23%) in
the no-adjuvant group suﬀered a local recurrence. The odds
ratio in favor of no adjuvant therapy for local recurrence
using both random and ﬁxed eﬀect models was 1.5 (95% CI,
0.67–3.35, P = .32) (Figure 2).
4.4. Heterogeneity and Publication Bias. The variability (I-
squared) in results across studies due to the true diﬀerences
intreatmenteﬀectwas0%,whichindicatesnoheterogeneity.
The funnel plot for all studies is asymmetrical (Figure 3)
indicating some publication bias in favor of studies showing
an eﬀect for the use of an adjuvant.
5. Discussion
Despite an abundance of published series on the surgical
management and outcomes of GCT of bone, there remains
a lack of consensus with respect to the need for a surgical
adjuvant when intralesional curettage is performed. We
have systematically reviewed the literature and identiﬁed six
studies in which two groups from the same patient cohort
were treated with intralesional curettage and high-speed
burring with or without a chemical or thermal adjuvant such
asphenol,liquidnitrogen,andPMMA.Pooleddatafrom387
patients did not indicate improved local control with the use
of surgical adjuvants.
These ﬁndings are signiﬁcant in light of recent pub-
lications claiming that chemical or thermal adjuvants are
requiredtoreducelocalrecurrenceinGCTofbone.Erraniet
al. reviewed a large series from a single institution in which
the recurrence rate for the 200 patients who underwent
intralesional curettage was 16% [21]. The authors deﬁned
“aggressive curettage” as one in which three local adjuvants
were used (phenol, alcohol, and cement) and “standard
curettage” as one in which phenol or alcohol was used but
not cement (allograft or autograft was used to ﬁll the defect).
The recurrence rate for the “aggressive curettage” group was
12.5% and for the “standard curettage” group was 18%.
These results were not statistically signiﬁcant and the study4 Sarcoma
Table 1: Characteristics of included studies.
Balke et al. [3] Boons et al. [24] D¨ urr et al. [12] O’Donnell et al. [9]T r i e b e t a l . [ 22] Turcotte et al.
[2]
Year of publication 2008 2002 1999 1994 2001 2002
Follow up (months) Mean 59.8 Mean 84 Median 61 Average 48 Median 132 Average 57
Ave Age (years) 33.4 years 34 years 33.5 31 33.5 36
Type of adjuvant PMMA PMMA +
Liquid Nitrogen
Phenol Phenol Phenol
Phenol, PMMA
and Liquid
Nitrogen
% axial lesions 6.5% 8% 0% 0% 15% 0%
(PMMA: Polymethyl methacrylate).
did not have a comparable group in which no adjuvants
were used. Kivioja et al. [14]a n dB e c k e re ta l .[ 11] published
multicenter studies in 2008 strongly concluding that PMMA
must be used to decrease recurrence rates in GCT of bone.
However, neither study was able to identify the patients in
the various treatment groups who underwent high-speed
burring and those that did not (author communications).
Both papers spanned several decades and the use of high-
speed burring likely coincided with the introduction of
chemical adjuvants. Therefore, despite these publications,
there remains no data to support the need for chemical
adjuvants if high-speed burring is employed.
In fact, results of other large series indicate that with
meticulous surgical technique and high-speed burring, local
control rates are comparable to other studies. Blackley et
al. reported a 12% recurrence rate in 59 patients treated
with intralesional curettage, high-speed burring, and bone
grafting [7]. Similarly, Prosser et al. reported a 19% recur-
rence rate in 137 patients treated with curettage and high-
speed burring alone [25]. Finally, the multicenter Canadian
study by Turcotte et al. reported a recurrence rate of 18% for
intralesional procedures in 148 patients and found that the
nature of the ﬁlling material used or the use of an adjuvant
failed to show any statistical impact on the recurrence risk
[2]. Thus the conclusion that adjuvants such as cement
are necessary to reduce recurrence in GCT of bone can be
debated by the results of these cohort studies.
The ideal forum to answer the question as to whether
an adjuvant is required would be a blinded randomized
controlled trial. However, due to the logistics of performing
such a study, the only available data at this time is obser-
vational as opposed to randomized. At the beginning of the
millennium, the New England Journal of Medicine published
two comprehensive studies comparing the point estimates
and conﬁdence intervals for various treatment outcomes
published in the medical literature [26, 27]. The authors
found convincing evidence that well-designed observational
studies do not overestimate treatment eﬀects and therefore
pooled observational data can lead to valuable conclusions if
randomized data is not available. The current meta-analysis
showed some heterogeneity between studies (although with-
out statistical signiﬁcance) and all studies were evaluated as
having acceptable methodology based on patient selection,
comparability, and exposure. The reason for failing to detect
2
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Figure 3: The funnel plot for the 6 studies included in the meta-
analysis. The plot shows asymmetrical distribution indicating some
publication bias in favor of studies showing an eﬀect for the use of
an adjuvant (to the left).
a signiﬁcant heterogeneity between studies is most likely due
to the fact that the included patients, particularly in the “no-
adjuvant” group, are small and the conﬁdence intervals in
the smaller studies are very wide. The pooling of the data,
however, serves to narrow the conﬁdence intervals and add
moreprecisiontothepointestimates.Inaddition, thefunnel
plot indicates publication bias in favor of a surgical adjuvant,
highlighting the importance of the nonsigniﬁcant eﬀects of
adjuvants in the pooled analysis.
In summary, we have systematically identiﬁed all studies
in the literature reporting recurrence rates in GCT follow-
ing intralesional curettage and high-speed burring with a
comparison group from the same cohort who underwent the
sameprocedureplusachemicalorthermaladjuvant.Despite
possible publication bias in favor of adjuvants, our results
support those of several groups who have concluded that
meticulous surgical technique including high-speed burring
is the most important step in reducing recurrence rates in
GCT of bone. Surgical procedures will remain the preference
of the individual surgeon. However, the claim that adjuvants
such as phenol and/or PMMA are necessary to reduce
recurrence rates is in fact not supported in the literature as
demonstrated by this work.Sarcoma 5
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